@article{Athanasakis2020-bu,
title = {Twenty-year trends in the prescription costs of Type 2 diabetes:
Real world data and empirical analysis in Greece},
author = {Kostas Athanasakis and Elisavet Prodromiadou and Athanasia Papazafiropoulou and Anastasios Koutsovasilis and Stamatina Driva and Maria Ziori and Elias Georgopoulos and Dimitris Gougourelas and Alexios Sotiropoulos and Stauros Bousboulas and Andreas Melidonis and Stauros Liatis},
year = {2020},
date = {2020-02-01},
journal = {Diabetes Res Clin Pract},
volume = {162},
pages = {108095},
address = {Ireland},
abstract = {AIMS: To estimate and compare the prescription costs for the
management of patients with diabetes over a period of 20 years in
Greece, based on real world data. METHODS: The records of
outpatients with T2D, monitored at three diabetes centres, were
examined in four cross-sections (1998, 2006, 2012, 2018).
Prescribed medicines per patient, along with a set of clinical
indicators were recorded. Annual costs of pharmaceutical
treatment per patient were calculated by using each year's
nominal retail prices, as well as by adjusting for 2018 price
levels, in order to account for price differences over time.
RESULTS: 4066 patients were included in the analysis.
Prescription patterns indicate a quick uptake of the new classes
of glucose-lowering drugs and a reduction in the proportional use
of sulfonylurea and glitazone. Adjusting for 2018 prices, the
average total annual prescription cost per patient was 381.54
Euros (s.d. 297.44) in 1998 and 1147.21 Euros (s.d. 814.39) in
2018. Glucose-lowering drug costs per patient increase from 1998
onwards, whereas the costs of antihypertensive, antiplatelet and
lipid-lowering treatment declined gradually, especially after
2006. CONCLUSIONS: Per patient prescription costs for
glucose-lowering drugs present a steep increase, in Greece over
the last 20 years. Real-world evidence studies that compare this
increase with the changes in patient outcomes are essential in
order to examine whether a costs-vs-outcomes balance is optimal.},
keywords = {Economic analysis; Glucose-lowering drugs cost; Prescription costs; Real world data},
pubstate = {published},
tppubtype = {article}
}
AIMS: To estimate and compare the prescription costs for the
management of patients with diabetes over a period of 20 years in
Greece, based on real world data. METHODS: The records of
outpatients with T2D, monitored at three diabetes centres, were
examined in four cross-sections (1998, 2006, 2012, 2018).
Prescribed medicines per patient, along with a set of clinical
indicators were recorded. Annual costs of pharmaceutical
treatment per patient were calculated by using each year's
nominal retail prices, as well as by adjusting for 2018 price
levels, in order to account for price differences over time.
RESULTS: 4066 patients were included in the analysis.
Prescription patterns indicate a quick uptake of the new classes
of glucose-lowering drugs and a reduction in the proportional use
of sulfonylurea and glitazone. Adjusting for 2018 prices, the
average total annual prescription cost per patient was 381.54
Euros (s.d. 297.44) in 1998 and 1147.21 Euros (s.d. 814.39) in
2018. Glucose-lowering drug costs per patient increase from 1998
onwards, whereas the costs of antihypertensive, antiplatelet and
lipid-lowering treatment declined gradually, especially after
2006. CONCLUSIONS: Per patient prescription costs for
glucose-lowering drugs present a steep increase, in Greece over
the last 20 years. Real-world evidence studies that compare this
increase with the changes in patient outcomes are essential in
order to examine whether a costs-vs-outcomes balance is optimal.